Arthritis News and Research

Latest Arthritis News and Research

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

SQI Diagnostics continues discussions with the FDA to market it's SQiDworks Diagnostics Platform in the US

SQI Diagnostics Inc. (TSX-V: SQD), a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced its financial and operational results for the third quarter ended June 30, 2009.

24 Aug 2009

Study reveals that treating Alzheimer's disease with DHA and EPA slows down its progression

Scientists have identified the inflammatory process as the common soil in a diverse range of chronic degenerative diseases. The news, recently reported in the LA Times article, discusses how foods like cherries may help rheumatoid arthritis or avoidance of gluten may fight off psoriasis.

24 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

Consumer-friendly "finger stick" blood test to detect cardiovascular disease is broadly available now

A new blood test, measuring the level of omega-3 fatty acids in red blood cells, is now broadly available for the first time to the public everywhere as a consumer-friendly, at-home "finger stick" test. While scientists have long known of the benefits of fish and fish oil for overall heart health, over the past decade research has proven that the omega-3 fatty acids found in fish dramatically reduce one's risk for cardiovascular disease. Further, recent research indicates that omega-3 levels may be among the best predictors of future coronary heart disease - providing much stronger correlations to the risk of sudden cardiac death than traditional indicators, including HDL and LDL cholesterol.

20 Aug 2009

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Steroid hormones found to affect gene activity

Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.

19 Aug 2009

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

4SC AG, the German drug discovery and development company, today announced the dosing of the first patient in its Phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option for patients with advanced hepatocellular carcinoma (HCC), the most frequent form of liver cancer.

18 Aug 2009

Human Genome Sciences achieves systemic lupus goals with candidate drug

Human Genome Sciences announced that BENLYSTA™ met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). These results show that BENLYSTA™ has the potential to become the first new approved drug in decades giving hope to people living with systemic lupus.

17 Aug 2009

How to stop osteoarthritis pain

When arthritis affects the hands, a range of treatments may reduce pain and preserve joint mobility. The August issue of Mayo Clinic Health Letter provides an overview.

13 Aug 2009

Marijuana/Cannabis may protect against osteoporosis

Scientists investigating the effects of cannabis on bone health have found that its impact varies dramatically with age.

13 Aug 2009

Pharmos reports Q2 2009 financials

Pharmos Corporation (Pink Sheets: PARS) today reported financial results for the second quarter and six-month period ended June 30, 2009.

12 Aug 2009

Biospecifics Technologies reports Q2 2009 financials

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the second quarter ended June 30, 2009.

12 Aug 2009

Meal replacements in a medically supervised weight loss program aid weight loss

Meal replacements in a medically supervised weight loss program are successful in facilitating weight loss, according to a new study conducted at the University of Kentucky. The study appears in the August 2009 issue of the Journal of the American Dietetic Association.

12 Aug 2009

New understanding of role hyaluronic acid in skeletal growth

Investigators at Burnham Institute for Medical Research (Burnham) and the University of Connecticut Health Center (U.C.H.C.) have gained new understanding of the role hyaluronic acid (HA) plays in skeletal growth, chondrocyte maturation and joint formation in developing limbs.

12 Aug 2009

Experimental treatment for multiple sclerosis reverses disorder in mice

A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder in mice, and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal.

11 Aug 2009

White tea shows most health benefits out of 21 plant and herb extracts

Next time you’re making a cuppa, new research shows it might be wise to opt for a white tea if you want to reduce your risk of cancer, rheumatoid arthritis or even just age-associated wrinkles. Researchers from Kingston University teamed up with Neal’s Yard Remedies to test the health properties of 21 plant and herb extracts. They discovered all of the plants tested had some potential benefits, but were intrigued to find white tea considerably outperformed all of them.

10 Aug 2009

Cephalon, Inc. completes acquisition of Arana Therapeutics

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has completed its previously announced acquisition of all of the outstanding ordinary shares of Australian biotechnology company, Arana Therapeutics Limited. As a result of the acquisition, Arana is now a wholly-owned subsidiary of Cephalon.

10 Aug 2009

Expert available on recent FDA analysis of TNF blockers

Lloyd J. Old, M.D., is Director of the Ludwig Institute for Cancer Research (LICR) New York Branch. He is also Director of the Cancer Research Institute (CRI) Scientific Advisory Council, Director of the CRI/LICR Cancer Vaccine Collaborative, and Director of the CRI Cancer Vaccine Consortium. He has been a Member of the National Academy of Sciences since 1978.

9 Aug 2009